세계의 급성기 의료 신드로믹 검사 시장 : 질환 유형별, 타겟별, 샘플 유형별, 최종 사용자별 - 예측(2025-2030년)

The Acute Care Syndromic Testing Market was valued at USD 3.40 billion in 2023, expected to reach USD 3.74 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 6.63 billion by 2030.

Acute care syndromic testing refers to the use of diagnostic tests that simultaneously detect multiple pathogens from a single sample, offering rapid and comprehensive results essential for quick decision-making in acute care settings. This testing is necessary due to the increasing prevalence of infectious diseases and the need for timely and accurate diagnosis to optimize treatment and improve patient outcomes. Applications are wide-ranging, including emergency rooms, urgent care, and intensive care units, where rapid pathogen identification can significantly impact treatment protocols. The end-use scope spans hospitals, diagnostic centers, and research institutes, underscoring its broad adoption potential.

Market growth is influenced by factors such as advancements in molecular diagnostic technologies, the integration of AI for enhanced predictive analytics, and growing awareness about the benefits of early and precise diagnostics. The rising incidence of infectious outbreaks, regulatory support for innovative diagnostics, and increasing healthcare spending further drive demand. Emerging opportunities lie in developing low-cost, portable diagnostic devices and expanding testing into remote and resource-poor settings, where accessibility significantly challenges healthcare delivery.

However, the market faces limitations such as high costs of advanced diagnostic tools, stringent regulatory requirements, and potential issues with test standardization. Moreover, the necessity for trained personnel to operate sophisticated equipment and interpret results adds to operational challenges, impacting adoption rates, especially in developing regions.

Innovation in acute care syndromic testing should focus on enhancing test specificity, reducing turnaround times, and integrating point-of-care devices with digital health platforms to facilitate remote monitoring and consultation. Continuous research into pathogen evolution patterns is essential to ensure effective diagnostic solutions remain updated for emerging threats. The nature of the market is dynamic, driven by technological advancements and evolving healthcare needs, indicating a vibrant landscape ripe for stakeholders to support innovation, collaborate on public health initiatives, and tackle the barriers hindering widespread market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Care Syndromic Testing Market

The Acute Care Syndromic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of infectious disease outbreaks
  • Utilization of syndromic tests for detecting antimicrobial resistance
  • Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
• Market Restraints
  • Incidences of false positives and false negatives and chances of contamination
• Market Opportunities
  • Efforts to include syndromic testing under stewardship programs
  • Advancements in clinical microbiology leading to improved testing strategies
• Market Challenges
  • Technical limitations of acute care syndromic testing methods

Porter's Five Forces: A Strategic Tool for Navigating the Acute Care Syndromic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Care Syndromic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Care Syndromic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Care Syndromic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Care Syndromic Testing Market

A detailed market share analysis in the Acute Care Syndromic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Care Syndromic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Care Syndromic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Care Syndromic Testing Market

A strategic analysis of the Acute Care Syndromic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Acute Care Syndromic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases, and Tropical Diseases.
• Based on Target, market is studied across Bacteria, Fungi, Parasites, and Viruses.
• Based on Sample Type, market is studied across Biofluids, Blood, Stool, Swabs, and Urine.
• Based on End User, market is studied across Clinical & Diagnostic Laboratories, Hospitals, and Research & Academic Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of infectious disease outbreaks
    • 5.1.1.2. Utilization of syndromic tests for detecting antimicrobial resistance
    • 5.1.1.3. Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of false positives and false negatives and chances of contamination
  • 5.1.3. Opportunities
    • 5.1.3.1. Efforts to include syndromic testing under stewardship programs
    • 5.1.3.2. Advancements in clinical microbiology leading to improved testing strategies
  • 5.1.4. Challenges
    • 5.1.4.1. Technical limitations of acute care syndromic testing methods
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
  • 5.2.2. Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
  • 5.2.3. Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
  • 5.2.4. End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Care Syndromic Testing Market, by Disease Type

• 6.1. Introduction
• 6.2. Gastrointestinal Diseases
• 6.3. Genitourinary Diseases
• 6.4. Respiratory Diseases
• 6.5. Tropical Diseases

7. Acute Care Syndromic Testing Market, by Target

• 7.1. Introduction
• 7.2. Bacteria
• 7.3. Fungi
• 7.4. Parasites
• 7.5. Viruses

8. Acute Care Syndromic Testing Market, by Sample Type

• 8.1. Introduction
• 8.2. Biofluids
• 8.3. Blood
• 8.4. Stool
• 8.5. Swabs
• 8.6. Urine

9. Acute Care Syndromic Testing Market, by End User

• 9.1. Introduction
• 9.2. Clinical & Diagnostic Laboratories
• 9.3. Hospitals
• 9.4. Research & Academic Institutions

10. Americas Acute Care Syndromic Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Acute Care Syndromic Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Acute Care Syndromic Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FDA Clears COVID-19 Home Antigen Test
  • 13.3.2. Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers
  • 13.3.3. NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Applied BioCode, Inc.
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Biocartis NV
• 6. BIOHM Health LLC
• 7. bioMerieux SA
• 8. Curetis GmbH b y OpGen, Inc
• 9. CVS Health
• 10. Danaher Corporation
• 11. DiaSorin S.p.A
• 12. Eurofins Scientific SE
• 13. F. Hoffmann-La Roche Ltd
• 14. Genetic Signatures Ltd.
• 15. Hologic Inc.
• 16. Luminex Corporation
• 17. Microbiologics, Inc.
• 18. Pfizer, Inc.
• 19. QIAGEN N.V.
• 20. QuantuMDx Group Ltd.
• 21. Seegene Inc.
• 22. Siemens Healthineers AG
• 23. Sysmex Corporation
• 24. Thermo Fisher Scientific Inc.
• 25. Werfen